[1] |
WHO. Update of recommendations on first- and second-line antiretroviral regimens. Geneva: WHO, 2019. |
[2] |
You JZ, Wang HR, Huang XJ, et al. Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: a subgroup meta-analysis of clinical trials. PLoS One, 2016; 11, e0160087. doi: 10.1371/journal.pone.0160087 |
[3] |
Zuo LL, Liu K, Liu HL, et al. Trend of HIV-1 drug resistance in China: a systematic review and meta-analysis of data accumulated over 17 years (2001−2017). E Clin Med, 2020; 18, 100238. doi: 10.1016/j.eclinm.2019.100238 |
[4] |
The Central People's Government of the People's Republic of China. Anhui province basic medical insurance drug list (implemented from January 1, 2020). http://www.audit.gov.cn/en/n751/index.html. [2020]. (In Chinese) |
[5] |
Hurt CB, Sebastian J, Hicks CB, et al. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009−2012. Clin Infect Dis, 2014; 58, 423−31. doi: 10.1093/cid/cit697 |
[6] |
Liu LF, Dai LL, Yao J, et al. Lack of HIV-1 integrase inhibitor resistance among 392 antiretroviral-naive individuals in a tertiary care hospital in Beijing, China. AIDS, 2019; 33, 1945−7. doi: 10.1097/QAD.0000000000002282 |
[7] |
Wensing AM, Calvez V, Ceccherini-Silberstein F, et al. 2019 update of the drug resistance mutations in HIV-1. Top Antivir Med, 2019; 27, 111−21. |
[8] |
Hassounah SA, Alikhani A, Oliveira M, et al. Antiviral activity of bictegravir and cabotegravir against integrase inhibitor-resistant SIVmac239 and HIV-1. Antimicrob Agents Chemother, 2017; 61, e01695−17. |
[9] |
Kobayashi M, Yoshinaga T, Seki T, et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother, 2011; 55, 813−21. doi: 10.1128/AAC.01209-10 |
[10] |
WHO. Guidelines on the public health response to pretreatment HIV drug resistance: July 2017. Geneva: WHO, 2017. |
[11] |
Hurt CB. Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule. Antivir Ther, 2011; 16, 137−40. doi: 10.3851/IMP1750 |